Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients

Inclusion Criteria: 1. Patient aged from 18 to 80 years and no gender preference; 2. Diagnosis of CVT as confirmed on MRBTI/MRV or CT/CTV or DSA; 3. Acute or subacute CVT from onset to door within 4 weeks; 4. The treating clinician irrelevant to the study is of the opinion that the patient is appropriate for edoxaban or rivaroxaban; 5. Patient or legally authorized representative is able to give written informed consent. Exclusion Criteria: 1. Patient refuse to take edoxaban or rivaroxaban to treat CVT; 2. Pregnancy or breastfeeding women at the time of enrollment, or women who plan to get pregnant during study; 3. Patient is anticipated to require invasive procedure (e.g. thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation; 4. CVT secondary to central nervous system infection or severe head trauma; 5. It is in the proliferative stage of malignant tumors currently or within 6 months of diagnosis; 6. Bleeding diathesis or other contraindication to anticoagulation; 7. Any concurrent medical condition requiring mandatory antiplatelet or anticoagulant use; 8. Concomitant use of strong CYP3A4 or P-gp inhibitors; 9. Impaired renal function (CrCl\<30 mL/min using Cockcroft-Gault equation) or investigator anticipate the CrCl lower than 30 mL/min during study; 10. Impaired liver function (ALT or AST exceeds twice the normal upper limit) or diagnosed as acute hepatitis currently; 11. Patient is unable to swallow due to depressed level of consciousness or other reasons; 12. Patient has a severe or fatal comorbid illness with life expectancy less than 6 months; 13. Patient with severe hypertension (SBP≥180mmHg and/or DBP≥110mmHg); 14. Patient is known to be allergic to edoxaban or rivaroxaban.